For the past some years I have observed that lot of new biotechnology companies have been spinning of every year from universities in Scandinavia and Netherlands. Some of these companies are into life sciences instrumentation, few into specialized formulations such as nanotechnology and major companies are into Recombinant protein production from different strains and then their further down stream purification ......Now for past 2-3 years the trend has been that lot of these incubator and specialised companies are been acquired or rather they go into licensing deals or mile stone payment options with the big daddies such as Pfizer, Novartis, GSK, Roche and Astra's...... GSK is a good example for a company which has rather decreased its investment on Research and development and has shifted its focus on investing in strategic alliances and acquisition of these biopharmaceutical companies in Scandinavia.
No comments:
Post a Comment